Swiss pharmaceutical and diagnostics giant Roche Group reported a strong financial performance for full-year 2025, with group sales rising 7 % at constant exchange rates, driven by solid demand for both medicines and diagnostic solutions, the company said in a media release on Thursday. Sales in the fourth quarter also grew by 8 %, underscoring continued momentum across its core businesses.
Roche’s Pharmaceuticals Division saw a 9 % increase in sales, led by key growth drivers including Phesgo for breast cancer, Xolair for allergic conditions, Ocrevus for multiple sclerosis, Hemlibra for haemophilia A and Vabysmo for severe eye diseases. The Diagnostics Division delivered a 2 % rise in sales, supported by sustained demand for pathology and molecular testing products despite pricing reforms in certain markets.
Profitability also improved markedly: core operating profit climbed 13 % and core earnings per share increased 11 %, while IFRS net income surged 58 % compared with the prior year, reflecting strong operational performance and the base effect of impairment charges in 2024.
Roche executives highlighted several regulatory and pipeline milestones in 2025, including US and EU approvals for a subcutaneous form of Lunsumio in a type of blood cancer, EU approval for Gazyva/Gazyvaro in lupus nephritis, and positive clinical data across multiple late-stage programmes from breast cancer and multiple sclerosis therapies to obesity candidate CT-388 advancing through late-stage trials.
On the diagnostics front, the company won CE marks for new tests, including an automated dengue antigen test and expanded mass spectrometry assays, enhancing Roche’s in-vitro diagnostic offerings and lab automation capabilities worldwide.
Looking ahead, Roche projected mid-single-digit sales growth in 2026 at constant exchange rates and continued increases in core earnings per share, underpinned by ongoing R&D investment and a strong product pipeline. The board also proposed a dividend increase, marking what would be the 39th consecutive annual raise if approved by shareholders.
Investors responded to the results against a backdrop of broader financial commentary, with some analysts noting that currency headwinds particularly from a stronger Swiss franc moderated reported growth in Swiss franc terms, even as underlying demand for key therapies remained robust.
